Shock Trauma Center, University of Maryland School of Medicine, Baltimore, MD, USA.
Department of Surgery, University of Maryland School of Medicine, Baltimore, MD, USA.
Mol Med. 2022 Oct 12;28(1):123. doi: 10.1186/s10020-022-00550-0.
Our previous data demonstrated that miR-19b expression was increased in human lung microvascular endothelial cells in-vitro-, in-vivo and in patients with hemorrhagic shock, leading to a decrease in syndecan-1 mRNA and protein and resulting in loss of endothelial barrier function. However, the mechanism underlying increased miR-19b expression remains unclear. The objective of the current study was to determine if c-Jun mediates the early responsive microRNA, miR-19b, to cause endothelial barrier dysfunction.
Human lung microvascular endothelial cells (HLMEC) or HEK293T cells were transfected with c-Jun overexpressing vector, c-Jun siRNA, miR-19b promoter vector, miR-19b mutated promoter vector, miR-19b oligo inhibitor, then subjected to hypoxia/reoxygenation as in-vitro model of hemorrhagic shock. Levels of protein, miRNA, and luciferase activity were measured. Transwell permeability of endothelial monolayers were also determined. Plasma levels of c-Jun were measured in injured patients with hemorrhagic shock.
Hypoxia/reoxygenation induced primary (pri-)miR-19b, mature miR-19b, and c-Jun expression over time in a comparable timeframe. c-Jun silencing by transfection with its specific siRNA reduced both pri-miR-19b and mature miR-19b levels. Conversely, c-Jun overexpression enhanced H/R-induced pri-miR-19b. Studies using a luciferase reporter assay revealed that in cells transfected with vectors containing the wild-type miR-19b promoter and luciferase reporter, c-Jun overexpression or hypoxia/ reoxygenation significantly increased luciferase activity. c-Jun knockdown reduced the luciferase activity in these cells, suggesting that the miR-19b promoter is directly activated by c-Jun. Further, chromatin immunoprecipitation assay confirmed that c-Jun directly bound to the promoter DNA of miR-19b and hypoxia/reoxygenation significantly increased this interaction. Additionally, c-Jun silencing prevented cell surface syndecan-1 loss and endothelial barrier dysfunction in HLMECs after hypoxia/reoxygenation. Lastly, c-Jun was significantly elevated in patients with hemorrhagic shock compared to healthy controls.
Transcription factor c-Jun is inducible by hypoxia/reoxygenation, binds to and activates the miR-19b promoter. Using an in-vitro model of hemorrhagic shock, our findings identified a novel cellular mechanism whereby hypoxia/ reoxygenation increases miR-19b transcription by inducing c-Jun and leads to syndecan-1 decrease and endothelial cell barrier dysfunction. This finding supports that miR-19b could be a potential therapeutic target for hemorrhage shock.
我们之前的数据表明,miR-19b 在体外、体内和失血性休克患者的人肺微血管内皮细胞中的表达增加,导致 syndecan-1mRNA 和蛋白减少,从而导致内皮屏障功能丧失。然而,miR-19b 表达增加的机制尚不清楚。本研究的目的是确定 c-Jun 是否介导早期反应性 microRNA miR-19b 引起内皮屏障功能障碍。
用 c-Jun 过表达载体、c-Jun siRNA、miR-19b 启动子载体、miR-19b 突变启动子载体、miR-19b 寡核苷酸抑制剂转染人肺微血管内皮细胞(HLMEC)或 HEK293T 细胞,然后进行缺氧/复氧作为失血性休克的体外模型。测量蛋白质、miRNA 和荧光素酶活性的水平。还测定了内皮单层的跨膜通透性。测量失血性休克损伤患者的血浆 c-Jun 水平。
缺氧/复氧诱导原发性(pri-)miR-19b、成熟 miR-19b 和 c-Jun 在可比的时间范围内随时间表达。用其特异性 siRNA 转染 c-Jun 沉默可降低 pri-miR-19b 和成熟 miR-19b 的水平。相反,c-Jun 的过表达增强了 H/R 诱导的 pri-miR-19b。使用荧光素酶报告基因检测的研究表明,在用含有野生型 miR-19b 启动子和荧光素酶报告基因的载体转染的细胞中,c-Jun 的过表达或缺氧/复氧显著增加了荧光素酶活性。c-Jun 敲低降低了这些细胞中的荧光素酶活性,表明 miR-19b 启动子可被 c-Jun 直接激活。进一步的染色质免疫沉淀分析证实 c-Jun 直接结合 miR-19b 的启动子 DNA,缺氧/复氧显著增加了这种相互作用。此外,c-Jun 沉默可防止缺氧/复氧后 HLMECs 表面 syndecan-1 的丢失和内皮屏障功能障碍。最后,与健康对照组相比,失血性休克患者的 c-Jun 显著升高。
转录因子 c-Jun 可被缺氧/复氧诱导,与 miR-19b 启动子结合并激活其活性。通过失血性休克的体外模型,我们的研究结果确定了一种新的细胞机制,即缺氧/复氧通过诱导 c-Jun 增加 miR-19b 转录,导致 syndecan-1 减少和内皮细胞屏障功能障碍。这一发现支持 miR-19b 可能是治疗失血性休克的潜在治疗靶点。